Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lutetium-177 Vipivotide Tetraxetan
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
LASER - a Phase 2 Trial of 177Lu-PSMA-617 as Systemic Therapy for Renal Cell Carcinoma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 11, 2025
Lead Product(s) : Lutetium-177 Vipivotide Tetraxetan
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lutetium-177 Vipivotide Tetraxetan
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : CHU de Quebec-Universite Laval | Novartis Pharmaceuticals Corporation | Canadian Institutes of Health Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 24, 2025
Lead Product(s) : Lutetium-177 Vipivotide Tetraxetan
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : CHU de Quebec-Universite Laval | Novartis Pharmaceuticals Corporation | Canadian Institutes of Health Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lutetium-177 Vipivotide Tetraxetan
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 26, 2024
Lead Product(s) : Lutetium-177 Vipivotide Tetraxetan
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lutetium-177 Vipivotide Tetraxetan
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : UMC Utrecht | Advanced Accelerator Applications
Deal Size : Inapplicable
Deal Type : Inapplicable
EBRT + Lu-PSMA for N1M0 Prostate Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 17, 2021
Lead Product(s) : Lutetium-177 Vipivotide Tetraxetan
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : UMC Utrecht | Advanced Accelerator Applications
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lutetium-177 Vipivotide Tetraxetan
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Prostate Cancer Foundation of Australia | Bristol Myers Squibb | Advanced Accelerator Applications | University of Sydney
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 09, 2021
Lead Product(s) : Lutetium-177 Vipivotide Tetraxetan
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Prostate Cancer Foundation of Australia | Bristol Myers Squibb | Advanced Accelerator Applications | University of Sydney
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lutetium-177 Vipivotide Tetraxetan
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 15, 2021
Lead Product(s) : Lutetium-177 Vipivotide Tetraxetan
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lutetium-177 Vipivotide Tetraxetan
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
177Lu-PSMA-617 Managed Access Program for mCRPC Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 01, 2021
Lead Product(s) : Lutetium-177 Vipivotide Tetraxetan
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lutetium-177 Vipivotide Tetraxetan
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Alliance Foundation Trials | RTOG Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 22, 2021
Lead Product(s) : Lutetium-177 Vipivotide Tetraxetan
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Alliance Foundation Trials | RTOG Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lutetium-177 Vipivotide Tetraxetan
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 30, 2020
Lead Product(s) : Lutetium-177 Vipivotide Tetraxetan
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lutetium-177 Vipivotide Tetraxetan
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Prostate Cancer Canada | Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 11, 2020
Lead Product(s) : Lutetium-177 Vipivotide Tetraxetan
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Prostate Cancer Canada | Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable